Harvard Bioscience Granted Nasdaq Compliance Extension

Harvard Bioscience ( (HBIO) ) just unveiled an announcement.

On October 2, 2025, Harvard Bioscience received a notification from Nasdaq granting an additional 180 days, until March 30, 2026, to comply with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market. The company’s stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective October 3, 2025, as part of this compliance effort. Failure to meet the requirement by the deadline could result in delisting, but the company plans to monitor its stock price and consider options like a reverse stock split to regain compliance.

The most recent analyst rating on (HBIO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.

Spark’s Take on HBIO Stock

According to Spark, TipRanks’ AI Analyst, HBIO is a Neutral.

Harvard Bioscience’s overall stock score reflects significant financial and valuation challenges, with profitability and leverage being major concerns. Technical analysis indicates potential stabilization, but bearish momentum persists. The earnings call provided some positive insights, particularly in cash flow and new product launches, but the overall outlook remains cautious due to revenue declines and external challenges.

To see Spark’s full report on HBIO stock, click here.

More about Harvard Bioscience

Harvard Bioscience, Inc. operates in the biotechnology industry, focusing on the development, manufacturing, and marketing of scientific instruments, systems, and consumables. The company primarily serves the life sciences research and drug discovery markets.

Average Trading Volume: 853,804

Technical Sentiment Signal: Sell

Current Market Cap: $19.94M

See more data about HBIO stock on TipRanks’ Stock Analysis page.